内源性硫化氢供体S-炔丙基半胱氨酸药理作用研究进展
Research Progress on Pharmacological Effects of S-Propargyl-Cysteine, the Endogenous Hydrogen Sulfide Donor
DOI: 10.12677/PI.2021.105035, PDF,    科研立项经费支持
作者: 席海燕, 李启秀：复旦大学药学院，上海；何先亮, 齐 炜：澳门科技大学药学院，澳门；勝呂綸貴子*：复旦大学药学院，上海;澳门科技大学药学院，澳门；茅以诚：复旦大学药学院，上海;复旦大学小分子活性物质上海市高校重点实验室，上海；朱依谆：复旦大学药学院，上海;澳门科技大学药学院，澳门;复旦大学小分子活性物质上海市高校重点实验室，上海
关键词: S-炔丙基半胱氨酸；硫化氢；药理作用；S-Propargyl-Cysteine； Hydrogen Sulfide； Pharmacological Effects
摘要: S-炔丙基半胱氨酸(S-propargyl-cysteine, SPRC)是通过对大蒜内含硫活性成分S-烯丙基半胱氨酸(SAC)结构修饰改造得到的新型内源性硫化氢(H2S)供体。研究发现，SPRC及其缓控释剂可以调控体内H2S水平，在多个心血管疾病模型中表现出良好的保护作用，可以通过发挥抗炎、抗氧化、抗纤维化等机制，起到保护心肌缺血、促进血管新生、稳定动脉粥样硬化斑块等作用。此外，SPRC在脑血管疾病、阿尔茨海默病、癌症、糖尿病肾病、子宫内膜异位症等疾病模型中也表现出良好的药理活性。本文通过文献查找和资料收集对SPRC药理作用研究进展进行综述，以期为SPRC的进一步研究提供参考。
Abstract: S-propargyl-cysteine (SPRC) is a novel endogenous hydrogen sulfide (H2S) donor obtained by modi-fying the structure of the sulfur-containing active ingredient S-allylcysteine (SAC) in garlic. Studies have found that SPRC and its controlled-release formulations can regulate the level of H2S in vivo and have shown effective protective effects in multiple cardiovascular disease models. SPRC has exerted anti-inflammatory, anti-oxidation and anti-fibrosis effects to protect ischemic myocardium, promote angiogenesis, and to stabilize atherosclerotic plaque, etc. In addition, SPRC also has shown great pharmacological activity in other disease models such as cerebrovascular disease, Alzheimer’s disease, cancer, diabetic nephropathy, and endometriosis. This article reviews the current research progress on pharmacological effects of SPRC through literature search and data collection, aiming at providing the reference for the further research of SPRC.
文章引用：席海燕, 何先亮, 李启秀, 勝呂綸貴子, 齐炜, 茅以诚, 朱依谆. 内源性硫化氢供体S-炔丙基半胱氨酸药理作用研究进展[J]. 药物资讯, 2021, 10(5): 274-282. https://doi.org/10.12677/PI.2021.105035

参考文献

[1] Wang, R. (2012) Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed. Physiological Reviews, 92, 791-896. [Google Scholar] [CrossRef] [PubMed]
[2] Wang, Q., Liu, H.R., Mu, Q., et al. (2009) S-Propargyl-Cysteine Protects Both Adult Rat Hearts and Neonatal Cardiomyocytes from Ischemia/Hypoxia Injury: The Contribution of the Hydrogen Sulfide-Mediated Pathway. Journal of Cardiovascular Pharmacology, 54, 139-146. [Google Scholar] [CrossRef] 
[3] Wu, J., Guo, W., Lin, S.Z., et al. (2016) Gp130-Mediated STAT3 Activation by S-Propargyl-Cysteine, an Endogenous Hydrogen Sulfide Initiator, Prevents Doxorubicin-Induced Cardiotoxicity. Cell Death & Disease, 7, e2339. [Google Scholar] [CrossRef] [PubMed]
[4] Liang, Y.H., Shen, Y.Q., Guo, W., et al. (2014) SPRC Protects Hy-poxia and Re-Oxygenation Injury by Improving Rat Cardiac Contractile Function and Intracellular Calcium Handling. Nitric Oxide, 41, 113-119. [Google Scholar] [CrossRef] [PubMed]
[5] Wu, D., Hu, Q., Tan, B., et al. (2018) Amelioration of Mitochon-drial Dysfunction in Heart Failure through S-Sulfhydration of Ca(2+)/Calmodulin-Dependent Protein Kinase II. Redox Biology, 19, 250-262. [Google Scholar] [CrossRef] [PubMed]
[6] Huang, C., Kan, J., Liu, X., et al. (2013) Cardioprotective Effects of a Novel Hydrogen Sulfide Agent-Controlled Release Formulation of S-Propargyl-Cysteine on Heart Failure Rats and Molecular Mechanisms. PLoS ONE, 8, e69205. [Google Scholar] [CrossRef] [PubMed]
[7] Tran, B.H., Huang, C., Zhang, Q., et al. (2015) Cardioprotective Effects and Pharmacokinetic Properties of a Controlled Release Formulation of a Novel Hydrogen Sulfide Donor in Rats with Acute Myocardial Infarction. Bioscience Reports, 35, e00216. [Google Scholar] [CrossRef] 
[8] Tran, B.H., Yu, Y., Chang, L., et al. (2019) A Novel Liposomal S-Propargyl-Cysteine: A Sustained Release of Hydrogen Sulfide Reducing Myocardial Fibrosis via TGF-β1/Smad Pathway. International Journal of Nanomedicine, 14, 10061-10077. [Google Scholar] [CrossRef] 
[9] Kan, J., Guo, W., Huang, C., et al. (2014) S-Propargyl-Cysteine, a Novel Water-Soluble Modulator of Endogenous Hydrogen Sulfide, Promotes Angiogenesis through Activation of Signal Transducer and Activator of Transcription 3. Antioxidants & Redox Signaling, 20, 2303-2316. [Google Scholar] [CrossRef] [PubMed]
[10] 熊青卉. 硫化氢及其内源性供体SPRC对动脉粥样硬化斑块稳定性的影响[D]: [博士学位论文]. 上海: 复旦大学药学院, 2013.
[11] 辛晓明. 炔丙基半胱氨酸(SPRC)对脑缺血再灌注损伤的保护作用及机制研究[D]: [博士学位论文]. 上海: 复旦大学药学院, 2016.
[12] Yang, H., Mao, Y., Tan, B., et al. (2015) The Protective Effects of Endogenous Hydrogen Sulfide Modulator, S-Propargyl-Cysteine, on High Glucose-Induced Apoptosis in Cardiomyocytes: A Novel Mechanism Mediated by the Activation of Nrf2. European Journal of Pharmacology, 761, 135-143. [Google Scholar] [CrossRef] [PubMed]
[13] Li, W., Ma, F., Zhang, L., et al. (2016) S-Propargyl-Cysteine Exerts a Novel Protective Effect on Methionine and Choline Deficient Diet-Induced Fatty Liver via Akt/Nrf2/HO-1 Pathway. Oxidative Medicine and Cellular Longevity, 2016, Article ID: 4690857. [Google Scholar] [CrossRef] [PubMed]
[14] Pan, L.L., Liu, X.H., Gong, Q.H., et al. (2011) S-Propargyl-Cysteine (SPRC) Attenuated Lipopolysaccharide-Induced Inflammatory Response in H9C2 Cells Involved in a Hydrogen Sul-fide-Dependent Mechanism. Amino Acids, 41, 205-215. [Google Scholar] [CrossRef] [PubMed]
[15] Pan, L.L., Liu, X.H., Zheng, H.M., et al. (2012) S-Propargyl-Cysteine, a Novel Hydrogen Sulfide-Modulated Agent, Attenuated Tumor Necrosis Factor-α-Induced Inflammatory Signaling and Dysfunction in Endothelial Cells. International Journal of Cardiology, 155, 327-332. [Google Scholar] [CrossRef] [PubMed]
[16] Sidhapuriwala, J.N., Hegde, A., Ang, A.D., et al. (2012) Effects of S-Propargyl-Cysteine (SPRC) in Caerulein-Induced Acute Pancreatitis in Mice. PLoS ONE, 7, e32574. [Google Scholar] [CrossRef] [PubMed]
[17] Wu, W.J., Jia, W.W., Liu, X.H., et al. (2016) S-Propargyl-Cysteine Attenuates Inflammatory Response in Rheumatoid Arthritis by Modulating the Nrf2-ARE Signal-ing Pathway. Redox Biology, 10, 157-167. [Google Scholar] [CrossRef] [PubMed]
[18] Yu, Y., Wang, Z., Ding, Q., et al. (2021) The Preparation of a Novel Poly(Lactic Acid)-Based Sustained H(2)S Releasing Microsphere for Rheumatoid Arthritis Alleviation. Pharma-ceutics, 13, 742. [Google Scholar] [CrossRef] [PubMed]
[19] Yu, Y., Wang, Z., Yang, Q., et al. (2021) A Novel Dendritic Mesoporous Silica Based Sustained Hydrogen Sulfide Donor for the Alleviation of Adjuvant-Induced Inflammation in Rats. Drug Delivery, 28, 1031-1042. [Google Scholar] [CrossRef] [PubMed]
[20] Wang, M., Tang, W., Xin, H., et al. (2016) S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of In-flammation by Inhibiting IL-6/STAT3 Pathway. PLoS ONE, 11, e0163289. [Google Scholar] [CrossRef] [PubMed]
[21] Hansen, D.V., Hanson, J.E. and Sheng, M. (2018) Microglia in Alzheimer’s Disease. Journal of Cell Biology, 217, 459-472. [Google Scholar] [CrossRef] [PubMed]
[22] Gong, Q.H., Wang, Q., Pan, L.L., et al. (2011) S-Propargyl-Cysteine, a Novel Hydrogen Sulfide-Modulated Agent, Attenuates Lipopolysaccharide-Induced Spatial Learning and Memory Impairment: Involvement of TNF Signaling and NF-κB Pathway in Rats. Brain, Behavior, and Immunity, 25, 110-119. [Google Scholar] [CrossRef] [PubMed]
[23] Gong, Q.H., Pan, L.L., Liu, X.H., et al. (2011) S-Propargyl-Cysteine (ZYZ-802), a Sulphur-Containing Amino Acid, Attenuates Beta-Amyloid-Induced Cognitive Def-icits and Pro-Inflammatory Response: Involvement of ERK1/2 and NF-κB Pathway in Rats. Amino Acids, 40, 601-610. [Google Scholar] [CrossRef] [PubMed]
[24] Ma, K., Liu, Y., Zhu, Q., et al. (2011) H2S Donor, S-Propargyl-Cysteine, Increases CSE in SGC-7901 and Cancer-Induced Mice: Evidence for a Novel Anti-Cancer Effect of Endogenous H2S? PLoS ONE, 6, e20525. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, W., Cheng, J., Zhu, Y. (2015) The JNK Signaling Path-way Is a Novel Molecular Target for S-Propargyl-Cysteine, a Naturally-Occurring Garlic Derivatives: Link to Its Anti-cancer Activity in Pancreatic Cancer in Vitro and in Vivo. Current Cancer Drug Targets, 15, 613-623. [Google Scholar] [CrossRef] [PubMed]
[26] Qian, X., Li, X., Ma, F., et al. (2016) Novel Hydrogen Sulfide-Releasing Compound, S-Propargyl-Cysteine, Prevents STZ-Induced Diabetic Nephropathy. Biochemical and Biophysical Research Communications, 473, 931-938. [Google Scholar] [CrossRef] [PubMed]
[27] 夏叶. 内外源性硫化氢供体在子宫内膜异位症及其粘连中作用探究[D]: [博士学位论文]. 上海: 复旦大学药学院, 2014.